AYTU
Income statement / Annual
Last year (2024), Aytu BioPharma, Inc.'s total revenue was $81.00 M,
a decrease of 24.58% from the previous year.
In 2024, Aytu BioPharma, Inc.'s net income was -$15.84 M.
See Aytu BioPharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
06/30/2024 |
06/30/2023 |
06/30/2022 |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
| Operating Revenue |
$81.00 M |
$107.40 M |
$96.67 M |
$65.63 M |
$27.63 M |
$7.32 M |
$3.66 M |
$3.22 M |
$2.56 M |
$261,782.00 |
| Cost of Revenue |
$26.42 M
|
$40.77 M
|
$44.39 M
|
$36.43 M
|
$7.55 M
|
$2.20 M
|
$2.05 M
|
$1.42 M
|
$957,076.00
|
$88,109.00
|
| Gross Profit |
$54.59 M
|
$66.63 M
|
$52.28 M
|
$29.20 M
|
$20.08 M
|
$5.12 M
|
$1.61 M
|
$1.80 M
|
$1.61 M
|
$173,673.00
|
| Gross Profit Ratio |
0.67
|
0.62
|
0.54
|
0.45
|
0.73
|
0.7
|
0.44
|
0.56
|
0.63
|
0.66
|
| Research and Development Expenses |
$2.79 M
|
$4.10 M
|
$14.44 M
|
$5.62 M
|
$1.72 M
|
$589,072.00
|
$167,595.00
|
$1.35 M
|
$6.32 M
|
$3.42 M
|
| General & Administrative Expenses |
$22.51 M
|
$28.63 M
|
$31.17 M
|
$25.50 M
|
$19.66 M
|
$0.00
|
$17.73 M
|
$17.61 M
|
$8.83 M
|
$4.38 M
|
| Selling & Marketing Expenses |
$26.96 M
|
$41.45 M
|
$38.71 M
|
$30.31 M
|
$11.40 M
|
$0.00
|
$0.00
|
-$242.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$49.47 M
|
$70.08 M
|
$69.88 M
|
$55.81 M
|
$34.80 M
|
$19.24 M
|
$17.73 M
|
$17.61 M
|
$8.83 M
|
$4.38 M
|
| Other Expenses |
$7.58 M
|
-$4.78 M
|
$4.07 M
|
$6.01 M
|
$4.49 M
|
$2.14 M
|
$6.28 M
|
$1.71 M
|
$664,707.00
|
$4,890.00
|
| Operating Expenses |
$60.57 M
|
$78.96 M
|
$88.39 M
|
$67.44 M
|
$41.01 M
|
$21.96 M
|
$19.45 M
|
$20.66 M
|
$15.81 M
|
$7.81 M
|
| Cost And Expenses |
$86.26 M
|
$119.73 M
|
$132.77 M
|
$103.87 M
|
$48.57 M
|
$24.17 M
|
$21.50 M
|
$22.08 M
|
$16.77 M
|
$7.89 M
|
| Interest Income |
$0.00
|
$9,000.00
|
$14,000.00
|
$6,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$4.79 M
|
$0.00
|
$147.50 M
|
$0.00
|
$0.00
|
$0.00
|
$749,423.00
|
$2.53 M
|
$5.49 M
|
$114,994.00
|
| Depreciation & Amortization |
$8.27 M
|
$8.82 M
|
$10.15 M
|
$7.70 M
|
$4.59 M
|
$2.24 M
|
$1.85 M
|
$1.84 M
|
$874,789.00
|
$118,202.00
|
| EBITDA |
-$1.01 M |
-$3.51 M |
-$27.96 M |
-$29.04 M |
-$12.21 M |
-$14.12 M |
-$15.25 M |
-$18.13 M |
-$21.81 M |
-$7.51 M |
| EBITDA Ratio |
-0.01
|
-0.07
|
0.43
|
-0.22
|
-0.89
|
-0.6
|
-2.45
|
-4.5
|
-5.2
|
-28.7
|
| Operating Income Ratio |
-0.06
|
-0.16
|
0.38
|
-0.58
|
-0.76
|
-2.3
|
-5.38
|
-6.25
|
-8.47
|
-29.16
|
| Total Other Income/Expenses Net |
-$8.82 M
|
$14,000.00
|
$1.02 M
|
$840,000.00
|
$7.51 M
|
-$10.29 M
|
$9.51 M
|
-$2.38 M
|
-$6.48 M
|
-$114,994.00
|
| Income Before Tax |
-$14.08 M
|
-$17.05 M
|
-$110.28 M
|
-$58.03 M
|
-$13.62 M
|
-$27.13 M
|
-$10.19 M
|
-$22.51 M
|
-$28.18 M
|
-$7.75 M
|
| Income Before Tax Ratio |
-0.17
|
-0.16
|
-1.14
|
-0.88
|
-0.49
|
-3.71
|
-2.78
|
-6.99
|
-11
|
-29.59
|
| Income Tax Expense |
$1.77 M
|
-$57,000.00
|
-$110,000.00
|
$259,000.00
|
-$9.92 M
|
$20.04 M
|
-$2.13 M
|
$1.11 M
|
$8.48 M
|
-$23,910.00
|
| Net Income |
-$15.84 M
|
-$17.05 M
|
-$108.78 M
|
-$58.29 M
|
-$13.62 M
|
-$47.17 M
|
-$10.19 M
|
-$22.51 M
|
-$28.18 M
|
-$7.72 M
|
| Net Income Ratio |
-0.2
|
-0.16
|
-1.14
|
-0.89
|
-0.13
|
-6.44
|
-2.78
|
-6.99
|
-11
|
-29.5
|
| EPS |
-2.86 |
-5.11 |
-74.01 |
-69.6 |
-60.2 |
-1210.28 |
-3061.23 |
-193194.38 |
-1294738.36 |
-551671.71 |
| EPS Diluted |
-2.86 |
-5.11 |
-74.01 |
-69.6 |
-60.2 |
-1210.28 |
-3061.23 |
-193194.38 |
-1294738.36 |
-551671.71 |
| Weighted Average Shares Out |
$5.54 M
|
$3.34 M
|
$1.47 M
|
$840,000.00
|
$230,000.00
|
$38,972.00
|
$3,328.03
|
$116.51
|
$21.77
|
$14.00
|
| Weighted Average Shares Out Diluted |
$5.54 M
|
$3.34 M
|
$1.47 M
|
$840,000.00
|
$230,000.00
|
$38,972.00
|
$3,328.03
|
$116.51
|
$21.77
|
$14.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
